Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535361 · ClinicalTrials.gov registry record · NA
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
A NA study of Short Bowel Syndrome, sponsored by Eclipse Regenesis.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT05535361: Recruiting NA study of Short Bowel Syndrome, sponsored by Eclipse Regenesis.
NCT05535361 is a NA study of Short Bowel Syndrome that is actively recruiting participants, run by Eclipse Regenesis. The registered enrollment target is 40 participants, below the 182-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (78% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535361, a NA study of Short Bowel Syndrome, is actively recruiting participants, sponsored by Eclipse Regenesis.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
Primary Outcome
Incident rate of moderate or severe procedure and/or device related adverse events
Conditions Studied
Interventions
- DEVICE Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Study Locations (6)
California
- Lucile Packard Children's Hospital Stanford - Palo Alto
- University of California San Francisco - San Francisco
- Stanford University School of Medicine - Stanford
District of Columbia
- Children's National Hospital - Washington D.C.
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT05535361 shows while recruiting
NCT05535361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 182-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome is the first listed.
NCT05535361 lists 6 locations in 4 states (California, District of Columbia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05535361 about?
NCT05535361 is a clinical study titled "A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome". A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
What is the current status of trial NCT05535361?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-09-15. Estimated completion is 2028-06-30.
What conditions does trial NCT05535361 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT05535361?
The interventions under investigation include: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome (DEVICE).
Who is sponsoring clinical trial NCT05535361?
This trial is sponsored by Eclipse Regenesis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535361 being conducted?
This trial has 6 study locations across California, District of Columbia, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05535361's enrollment target sits among peer trials
40 12th of 17 higher than 5 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Registry for Participants With Short Bowel Syndrome
ACTIVE NOT RECRUITING
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI